Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Auspep
Tullamarine, Victoria, Australia
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Auspep manufactures GMP-grade synthetic peptides, including APIs for preclinical, clinical, and commercial supply. It supports pharma, biotech, and academic partners globally. It is recognized for producing IK-14800, an immunomodulating peptide in preclinical studies for basal cell carcinoma and other skin cancers[5].
- Therapeutic areas
- OncologyDermatology
- Modalities
- PeptidesSynthetic peptide
- Industry
- Biotech
02
Partnerships
Argenica TherapeuticsPharmaciaGlaxoSmithKlinePfizer Animal HealthMayne PharmaceuticalsFerring PharmaceuticalsMetabolic Pharmaceuticals LtdHoward Florey/Austin HospitalUniversity of EdinburghUniversity of MinnesotaGBS Venture Partners LtdHunter Immunology Pty LtdPeptech Ltd
Beyond the preview
Go deeper on Auspep.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Auspep.